National Research Corporation Announces First Quarter 2019 Results
May 07 2019 - 5:00PM
National Research Corporation (NASDAQ: NRC) today announced results
for the first quarter of 2019.
- Net New Sales of $4.1 million
- Net Income increased to $8.2 million
- 650+ core clients achieve Contract Value CAGR of 20%
Commenting on recent performance, Michael D.
Hays, chief executive officer of National Research Corporation
said, “The Company’s shift from its legacy mix of business in favor
of our VoC platform with embedded tools such as Transparency and
Care Transitions, has surpassed 20% CAGR for our 650+ core clients.
This group of clients now accounts for $101 million of contract
value, up from $53 million at year-end 2015.”
Revenue for the quarter ended March 31, 2019 was
$31.5 million, compared to $31.0 million for the same quarter in
2018. Net income for the quarter ended March 31, 2019, was $8.2
million, compared to $7.3 million for the quarter ended March 31,
2018. Diluted earnings per share increased to $0.32 for the common
stock (formerly Class A) for the quarter ended March 31, 2019, from
diluted earnings per share of $0.17 for Class A shares and $1.01
for Class B shares for the quarter ended March 31, 2018. Due to the
recapitalization transaction on April 17, 2018, income has been
allocated to both classes of shares through April 16, 2018, and
allocated only to common stock (formerly Class A) after April 16,
2018.
Regarding the Company’s first quarter financial
performance, Kevin Karas, chief financial officer of National
Research Corporation, said, “We achieved record high operating
margins in the first quarter, due in large part to variable cost
savings driven by the shift in our revenue mix from legacy
solutions to VoC platform revenue. On a cumulative basis, through
the first quarter of 2019, this shift in revenue mix represents
over $12 million in lower variable cost of product expense since
the end of 2015. Our continued focus on adding new customers to the
VoC platform solution and driving value for existing customers
resulted in an increase in total contract value in the first
quarter of 7% over prior year.”
A listen-only simulcast of National Research
Corporation’s 2019 first quarter conference call will be available
online at http://edge.media-server.com/m6/p/b2o44bov on May 8,
2019, beginning at 11:00 a.m. Eastern time. The online replay will
follow approximately one hour later and continue for 30
days.
For more than 38 years, National Research Corporation has been a
leading provider of analytics and insights that facilitate
measurement and improvement of the patient and employee experience
while also increasing patient engagement and customer loyalty for
healthcare providers, payers and other healthcare organizations in
the United States and Canada. The Company’s solutions enable
its clients to understand the voice of the customer with greater
clarity, immediacy and depth.
This press release includes “forward-looking”
statements related to the Company that can generally be identified
as describing the Company’s future plans, objectives or
goals. Such forward-looking statements are subject to risks
and uncertainties that could cause actual results or outcomes to
differ materially from those currently anticipated. These
forward-looking statements are made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of
1995. For further information about the factors that could
affect the Company’s future results, please see the Company’s
filings with the Securities and Exchange Commission.
Contact: Kevin R. Karas
Chief Financial
Officer402-475-2525
NATIONAL RESEARCH
CORPORATION AND
SUBSIDIARYUnaudited Condensed
Consolidated Statements of Income(In thousands, except per
share data)
|
Three
months ended March 31, |
|
|
|
2019 |
|
|
|
2018 |
|
|
|
|
Revenue |
$ |
31,480 |
|
|
$ |
31,017 |
|
|
|
|
Operating
expenses: |
|
|
Direct |
|
11,654 |
|
|
|
12,909 |
|
Selling,
general and administrative |
|
7,707 |
|
|
|
7,867 |
|
Depreciation
and amortization |
|
1,415 |
|
|
|
1,283 |
|
Total
operating expenses |
|
20,776 |
|
|
|
22,059 |
|
|
|
|
Operating income |
|
10,704 |
|
|
|
8,958 |
|
|
|
|
Other income
(expense): |
|
|
Interest income |
|
6 |
|
|
|
45 |
|
Interest expense |
|
(570 |
) |
|
|
(8 |
) |
Other, net |
|
(280 |
) |
|
|
(28 |
) |
|
|
|
Total
other income (expense) |
|
(844 |
) |
|
|
9 |
|
|
|
|
Income before income taxes |
|
9,860 |
|
|
|
8,967 |
|
|
|
|
Provision
for income taxes |
|
1,664 |
|
|
|
1,661 |
|
|
|
|
Net
income |
$ |
8,196 |
|
|
$ |
7,306 |
|
|
|
|
Earnings Per Share of Common Stock: |
|
|
Basic Earnings Per Share: |
|
|
Common (formerly Class A) |
$ |
0.33 |
|
|
$ |
0.17 |
|
Class B |
$ |
-- |
|
|
$ |
1.04 |
|
Diluted Earnings Per Share: |
|
|
Common (formerly Class A) |
$ |
0.32 |
|
|
$ |
0.17 |
|
Class B |
$ |
-- |
|
|
$ |
1.01 |
|
|
|
|
Weighted
average shares and share equivalents outstanding Common
(formerly Class A) - Basic |
|
24,766 |
|
|
|
20,884 |
|
Class
B - Basic |
|
-- |
|
|
|
3,527 |
|
Common (formerly Class A) - Diluted |
|
25,509 |
|
|
|
21,837 |
|
Class
B - Diluted |
|
-- |
|
|
|
3,630 |
|
NATIONAL RESEARCH
CORPORATION AND
SUBSIDIARYUnaudited Condensed
Consolidated Balance Sheets(Dollars in thousands, except
per share amounts and par value)
|
|
March 31, 2019 |
|
|
December 31,
2018 |
|
|
|
(unaudited) |
|
|
|
|
|
Assets |
|
|
|
|
|
|
|
|
Current assets: |
|
|
|
|
|
|
|
|
Cash and
cash equivalents |
|
$ |
2,641 |
|
|
$ |
12,991 |
|
Accounts
receivable, net |
|
|
15,888 |
|
|
|
11,922 |
|
Income
taxes receivable |
|
|
217 |
|
|
|
348 |
|
Other
current assets |
|
|
4,127 |
|
|
|
3,149 |
|
Total
current assets |
|
|
22,873 |
|
|
|
28,410 |
|
|
|
|
|
|
|
|
|
|
Net
property and equipment |
|
|
13,968 |
|
|
|
14,153 |
|
Goodwill |
|
|
57,877 |
|
|
|
57,831 |
|
Other,
net |
|
|
9,853 |
|
|
|
7,638 |
|
Total
assets |
|
$ |
104,571 |
|
|
$ |
108,032 |
|
|
|
|
|
|
|
|
|
|
Liabilities and Shareholders’ Equity |
|
|
|
|
|
|
|
|
Current
liabilities: |
|
|
|
|
|
|
|
|
Notes
payable and line of credit |
|
$ |
5,464 |
|
|
$ |
3,667 |
|
Accounts
payable and accrued expenses |
|
|
4,101 |
|
|
|
3,447 |
|
Accrued
compensation |
|
|
4,017 |
|
|
|
5,798 |
|
Income
taxes payable |
|
|
1,763 |
|
|
|
636 |
|
Dividends
payable |
|
|
4,724 |
|
|
|
17,113 |
|
Deferred
revenue |
|
|
18,241 |
|
|
|
16,244 |
|
Other
current liabilities |
|
|
928 |
|
|
|
204 |
|
Total
current liabilities |
|
|
39,238 |
|
|
|
47,109 |
|
|
|
|
|
|
|
|
|
|
Non-current liabilities |
|
|
42,594 |
|
|
|
41,840 |
|
Total
liabilities |
|
|
81,832 |
|
|
|
88,949 |
|
|
|
|
|
|
|
|
|
|
Shareholders’
equity: |
|
|
|
|
|
|
|
|
Preferred
stock, $0.01 par value, authorized 2,000,000 shares, none
issued |
|
|
-- |
|
|
|
-- |
|
Common
stock, $0.001 par value; authorized 60,000,000 shares, issued
30,009,919 in 2019 and 29,917,667 in 2018, outstanding 24,864,391
in 2019 and 24,800,796 in 2018 |
|
|
30 |
|
|
|
30 |
|
Additional paid-in capital |
|
|
158,247 |
|
|
|
157,312 |
|
Retained
earnings (accumulated deficit) |
|
|
(102,867 |
) |
|
|
(106,339 |
) |
Accumulated other comprehensive loss, foreign currency translation
adjustment |
|
|
(2,551 |
) |
|
|
(2,916 |
) |
Treasury
stock |
|
|
(30,120 |
) |
|
|
(29,004 |
) |
Total
shareholders’ equity |
|
|
22,739 |
|
|
|
19,083 |
|
Total
liabilities and shareholders’ equity |
|
$ |
104,571 |
|
|
$ |
108,032 |
|
National Research (NASDAQ:NRC)
Historical Stock Chart
From Jun 2024 to Jul 2024
National Research (NASDAQ:NRC)
Historical Stock Chart
From Jul 2023 to Jul 2024